The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
O Tournilhac - One of the best experts on this subject based on the ideXlab platform.
-
combination of rituximab bortezomib Doxorubicin dexamethasone and chlorambucil ripad c as first line therapy for elderly mantle cell lymphoma patients results of a phase ii trial from the goelams
Annals of Oncology, 2012Co-Authors: Roch Houot, Le S Gouill, Ojeda M Uribe, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Alexis M Vigier, Mariepierre Moles, O TournilhacAbstract:ABSTRACT Background There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. Patients and methods Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. Results Thirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. Conclusion The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
-
Combination of rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Annals of Oncology, 2012Co-Authors: Roch Houot, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Mariepierre Moles, Steven Le Gouill, Mario Ojeda Uribe, M. Alexis Vigier, O TournilhacAbstract:BACKGROUND: There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. PATIENTS AND METHODS: Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. RESULTS: Thirty-nine patients were enrolled. Median age was 72 years (65-80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. CONCLUSION: The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
Roch Houot - One of the best experts on this subject based on the ideXlab platform.
-
combination of rituximab bortezomib Doxorubicin dexamethasone and chlorambucil ripad c as first line therapy for elderly mantle cell lymphoma patients results of a phase ii trial from the goelams
Annals of Oncology, 2012Co-Authors: Roch Houot, Le S Gouill, Ojeda M Uribe, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Alexis M Vigier, Mariepierre Moles, O TournilhacAbstract:ABSTRACT Background There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. Patients and methods Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. Results Thirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. Conclusion The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
-
Combination of rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Annals of Oncology, 2012Co-Authors: Roch Houot, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Mariepierre Moles, Steven Le Gouill, Mario Ojeda Uribe, M. Alexis Vigier, O TournilhacAbstract:BACKGROUND: There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. PATIENTS AND METHODS: Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. RESULTS: Thirty-nine patients were enrolled. Median age was 72 years (65-80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. CONCLUSION: The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
D R Parkinson - One of the best experts on this subject based on the ideXlab platform.
-
randomized comparison of Doxorubicin alone versus ifosfamide plus Doxorubicin or mitomycin Doxorubicin and cisplatin against advanced soft tissue sarcomas
Journal of Clinical Oncology, 1993Co-Authors: John H. Edmonson, Louise Ryan, Ronald H Blum, John S J Brooks, M Shiraki, S Frytak, D R ParkinsonAbstract:PURPOSEThis three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving Doxorubicin alone, ifosfamide plus Doxorubicin, and mitomycin plus Doxorubicin plus cisplatin.PATIENTS AND METHODSBetween December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (Doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus Doxorubicin 60 mg/m2), or treatment C (mitomycin 8 mg/m2 plus Doxorubicin 40 mg/m2 plus cisplatin 60 mg/m2).RESULTSOf 262 assessable patients, 74 (29%) achieved objective tumor regression. Objective regression occurred in 20% of the 90 patients who received Doxorubicin alone (complete remission [CR] rate, 2%), in 34% of the 88 who received ifosfamide plus Doxorubicin (CR rate, 3%), and in 32% of the 84 who received mitomycin plus Doxorubicin plus cisplatin (CR rate, 7%). With grade 3 or greater myelosuppression in 53% of gr...
Caroline Dartigeas - One of the best experts on this subject based on the ideXlab platform.
-
combination of rituximab bortezomib Doxorubicin dexamethasone and chlorambucil ripad c as first line therapy for elderly mantle cell lymphoma patients results of a phase ii trial from the goelams
Annals of Oncology, 2012Co-Authors: Roch Houot, Le S Gouill, Ojeda M Uribe, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Alexis M Vigier, Mariepierre Moles, O TournilhacAbstract:ABSTRACT Background There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. Patients and methods Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. Results Thirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. Conclusion The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
-
Combination of rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Annals of Oncology, 2012Co-Authors: Roch Houot, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Mariepierre Moles, Steven Le Gouill, Mario Ojeda Uribe, M. Alexis Vigier, O TournilhacAbstract:BACKGROUND: There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. PATIENTS AND METHODS: Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. RESULTS: Thirty-nine patients were enrolled. Median age was 72 years (65-80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. CONCLUSION: The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
Stephane Courby - One of the best experts on this subject based on the ideXlab platform.
-
combination of rituximab bortezomib Doxorubicin dexamethasone and chlorambucil ripad c as first line therapy for elderly mantle cell lymphoma patients results of a phase ii trial from the goelams
Annals of Oncology, 2012Co-Authors: Roch Houot, Le S Gouill, Ojeda M Uribe, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Alexis M Vigier, Mariepierre Moles, O TournilhacAbstract:ABSTRACT Background There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. Patients and methods Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. Results Thirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. Conclusion The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
-
Combination of rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Annals of Oncology, 2012Co-Authors: Roch Houot, Christiane Mounier, Stephane Courby, Caroline Dartigeas, Kamal Bouabdallah, Mariepierre Moles, Steven Le Gouill, Mario Ojeda Uribe, M. Alexis Vigier, O TournilhacAbstract:BACKGROUND: There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, Doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, Doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, Doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL. PATIENTS AND METHODS: Patients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C. RESULTS: Thirty-nine patients were enrolled. Median age was 72 years (65-80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity. CONCLUSION: The bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL.
